MedTrace Logo

Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor

NCT03395730 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-01-10

No results posted yet for this study

Summary

The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor.

Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?

Conditions

  • Postpartum Haemorrhage With Retained Placenta

Interventions

DRUG

Intraumbilical vein injection oxytocin

intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.

PROCEDURE

placental cord drainage

placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

PROCEDURE

Expectant managment of 3rd stage of labour

Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.

Sponsors & Collaborators

  • Eslam Mohammed Abbas

    lead OTHER

Principal Investigators

  • Tamer F Borg, MD · Ain Shams University

  • Bassem I Ali, MD · Ain Shams University

  • Islam M Abbas, MBBch · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-30
Primary Completion
2018-01-15
Completion
2018-01-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395730 on ClinicalTrials.gov